EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Varnimcabtagene autoleucel (ARI‐0001) in relapsed or refractory mantle cell lymphoma

Nil Albiol iD, Nuria Martínez-Cibrián, Amanda Isabel Pérez, Sergio Navarro-Velázquez, Guilherme Muzzi, Aina Oliver-Caldes, Marta Español-Rego, Leticia Alserawan, Mercedes Montoro-Lorite, Carla Ramos, Pilar Ayora, Ana África Martin-López und 30 weitere

HemaSphere · 2026-05 · 10 (5)

DOI: 10.1002/hem3.70388 ↗

Kurz gefasst

Fachartikel in der Zeitschrift HemaSphere, online erschienen am 21.05.2026. Verfasst von Nil Albiol und 41 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology Hospital Clínic de Barcelona Barcelona Spain. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Instituto de Salud Carlos III.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Varnimcabtagene autoleucel (var‐cel) is an autologous CD19‐directed chimeric antigen receptor (CAR) T‐cell therapy administered using an adaptive, fractionated dosing strategy. We conducted a multicenter retrospective study to evaluate the safety and efficacy of var‐cel in patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL) treated at four Spanish centers, including patients enrolled in the CART19‐BE‐01 trial and a subsequent compassionate use program. Thirty patients underwent leukapheresis; 27 received var‐cel following lymphodepletion and fractionated infusion in three escalating doses (0.1 to 5 × 10 6 CAR T cells/kg). Any‐grade cytokine release syndrome (CRS) and immune effector cell‐associated neurotoxicity syndrome (ICANS) occurred in 93% and 4%, respectively, with Grade ≥3 CRS and/or ICANS observed in a single patient (4%). The overall response rate among infused patients was 89% (95% CI, 71–98), including 78% complete responses (95% CI, 58–91). Median duration of response and progression‐free survival were 17.1 and 15.4 months, respectively. With a median follow‐up of 21.7 months, median overall survival was 35.2 months. In this multicenter academic experience, var‐cel demonstrated high antitumor activity with low rates of severe CRS and ICANS, supporting its use within a coordinated national network.

Autor:innen und Institutionen

  • Department of Hematology Hospital Clínic de Barcelona Barcelona Spain.
  • Fundació de Recerca Clínic Barcelona - Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS) Barcelona Spain.
  • Facultat de Medicina Universitat de Barcelona (UB) Barcelona Spain.
  • Hematopathology Section, Pathology Department Hospital Clínic de Barcelona Barcelona Spain.
  • Department of Immunology Hospital Clínic de Barcelona Barcelona Spain.
  • Department of Hematology Hospital da Policia Militar de Minas Gerais Belo Horizonte Minas Gerais Brazil.

ORCID-Profile: Nil Albiol, Mariana Bastos-Oreiro, Pablo Mozas, Carlos Fernández de Larrea, Julio Delgado

Förderung

  • Instituto de Salud Carlos III

Zitieren

APA

Albiol, N., Martínez-Cibrián, N., Pérez, A. I., Navarro-Velázquez, S., Muzzi, G., Oliver-Caldes, A., Español-Rego, M., Alserawan, L., Montoro-Lorite, M., Ramos, C., Ayora, P., Martin-López, A. Á., Cabero, A., Pérez-López, E., García-Sancho, A. M., Baumann, T., Sánchez-Pina, J. M., Chinea, A., Fernández-Caldas, P., …, & Ortiz-Maldonado, V. (2026). Varnimcabtagene autoleucel (ARI‐0001) in relapsed or refractory mantle cell lymphoma. HemaSphere, 10(5). https://doi.org/10.1002/hem3.70388

Vancouver

Albiol N, Martínez-Cibrián N, Pérez AI, Navarro-Velázquez S, Muzzi G, Oliver-Caldes A, et al. Varnimcabtagene autoleucel (ARI‐0001) in relapsed or refractory mantle cell lymphoma. HemaSphere. 2026;10(5). doi:10.1002/hem3.70388

BibTeX
@article{Albiol2026,
  author = {Albiol, Nil and Martínez-Cibrián, Nuria and Pérez, Amanda Isabel and Navarro-Velázquez, Sergio and Muzzi, Guilherme and Oliver-Caldes, Aina and Español-Rego, Marta and Alserawan, Leticia and Montoro-Lorite, Mercedes and Ramos, Carla and Ayora, Pilar and Martin-López, Ana África and Cabero, Almudena and Pérez-López, Estefanía and García-Sancho, Alejandro Martín and Baumann, Tycho and Sánchez-Pina, José María and Chinea, Anabelle and Fernández-Caldas, Paula and Bastos-Oreiro, Mariana and Kwon, Mi and Rodríguez-Lobato, Luis Gerardo and Magnano, Laura and Rivero, Andrea and Correa, Juan G and Mozas, Pablo and Sánchez-Castañón, María and Mata-Molanes, Juan J and Charry, Paola and Álamo, Jose R and Setoaín, Xavier and Rodríguez, Sonia and Olesti, Eulalia and Sáez-Peñataro, Joaquín and Fernández de Larrea, Carlos and Urbano-Ispizua, Álvaro and López-Guillermo, Armando and Delgado, Julio and González-Navarro, E Azucena and Juan, Manel and Giné, Eva and Ortiz-Maldonado, Valentín},
  title = {Varnimcabtagene autoleucel (ARI‐0001) in relapsed or refractory mantle cell lymphoma},
  journal = {HemaSphere},
  year = {2026},
  volume = {10},
  number = {5},
  doi = {10.1002/hem3.70388}
}
Kostenlos starten →